{"id":"W4390004386","doi":"10.1080/2162402x.2023.2290787","title":"A phase 2, multicenter, open-label study of anti-LAG-3 ieramilimab in combination with anti-PD-1 spartalizumab in patients with advanced solid malignancies","year":2023,"lang":"en","type":"article","venue":"OncoImmunology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Alberta; Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"National Cancer Institute; University of Texas MD Anderson Cancer Center; Society for Immunotherapy of Cancer; Novartis Pharmaceuticals Corporation","keywords":"Medicine; Rash; Internal medicine; Renal cell carcinoma; Oncology; Melanoma; Nausea; Response Evaluation Criteria in Solid Tumors; Clinical endpoint; Adverse effect; Cancer; Phases of clinical research; Nivolumab; Immunotherapy; Clinical trial; Cancer research","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002308255,0.001802501,0.002471684,0.0005286235,0.0004374287,0.0008560047,0.000760986,0.0009865307,0.002360658],"category_scores_gemma":[0.001027383,0.000860605,0.001399271,0.0004847904,0.0009714096,0.001086239,0.0003457798,0.002849185,0.0007293257],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008832722,"about_ca_system_score_gemma":0.001459398,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006437899,"about_ca_topic_score_gemma":0.001483255,"domain_scores_codex":[0.9993531,0.0003468741,0.00003011926,0.0001163421,0.00005782581,0.00009577141],"domain_scores_gemma":[0.9992852,0.0001229375,0.000151046,0.00007491204,0.00004784098,0.0003180203],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7004327,0.1440237,0.01088209,0.0006642477,0.001439404,0.0002940181,0.0004272271,0.002449044,0.0556347,0.000248851,0.002732133,0.0807718],"study_design_scores_gemma":[0.4836914,0.5015063,0.009291847,0.00001367971,0.0002857729,0.0001933999,0.00004130986,0.0009638344,0.002413433,0.0001042734,0.001470755,0.0000240735],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.994399,0.00116248,0.0005986387,0.0002156415,0.0000839714,0.002147495,0.0005610774,0.00007599711,0.000755742],"genre_scores_gemma":[0.9899371,0.001111048,0.002336862,0.0005530594,0.0002317451,0.002838289,0.00157061,0.00003078936,0.001390516],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002471684,"threshold_uncertainty_score":0.01220733,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02640003130830229,"score_gpt":0.3339655591300359,"score_spread":0.3075655278217336,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}